These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 22672259)

  • 21. Intravitreal bevacizumab as supplemental treatment or monotherapy for severe retinopathy of prematurity.
    Axer-Siegel R; Snir M; Ron Y; Friling R; Sirota L; Weinberger D
    Retina; 2011; 31(7):1239-47. PubMed ID: 21555969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pain assessment in premature infants treated with intravitreal antiangiogenic therapy for retinopathy of prematurity under topical anesthesia.
    Castellanos MA; Schwartz S; Leal R; Chan RV; Quiroz-Mercado H
    Graefes Arch Clin Exp Ophthalmol; 2013 Feb; 251(2):491-4. PubMed ID: 22619071
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravitreal bevacizumab following laser therapy for severe retinopathy of prematurity.
    Erol N; Gürsoy H; Sahin A; Basmak H
    J Pediatr Ophthalmol Strabismus; 2010 Aug; 47 Online():e1-4. PubMed ID: 21158371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-vascular endothelial growth factor intravitreal therapy for retinopathy of prematurity.
    VanderVeen DK; Cataltepe SU
    Semin Perinatol; 2019 Oct; 43(6):375-380. PubMed ID: 31174872
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study.
    Kong L; Mintz-Hittner HA; Penland RL; Kretzer FL; Chévez-Barrios P
    Arch Ophthalmol; 2008 Aug; 126(8):1161-3. PubMed ID: 18695118
    [No Abstract]   [Full Text] [Related]  

  • 26. Retinal fluorescein angiographic changes following intravitreal anti-VEGF therapy.
    Henaine-Berra A; Garcia-Aguirre G; Quiroz-Mercado H; Martinez-Castellanos MA
    J AAPOS; 2014 Apr; 18(2):120-3. PubMed ID: 24698606
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravitreal bevacizumab for exudative retinal detachment post laser therapy for retinopathy of prematurity.
    Ehmann D; Greve M
    Can J Ophthalmol; 2014 Apr; 49(2):228-31. PubMed ID: 24767234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity.
    Wu WC; Lien R; Liao PJ; Wang NK; Chen YP; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC
    JAMA Ophthalmol; 2015 Apr; 133(4):391-7. PubMed ID: 25569026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primary intravitreal ranibizumab for high-risk retinopathy of prematurity.
    Baumal CR; Goldberg RA; Fein JG
    Ophthalmic Surg Lasers Imaging Retina; 2015 Apr; 46(4):432-8. PubMed ID: 25970863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reactivation of retinopathy of prematurity after ranibizumab treatment.
    Wong RK; Hubschman S; Tsui I
    Retina; 2015 Apr; 35(4):675-80. PubMed ID: 25768252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in taiwan.
    Wu WC; Kuo HK; Yeh PT; Yang CM; Lai CC; Chen SN
    Am J Ophthalmol; 2013 Jan; 155(1):150-158.e1. PubMed ID: 22967867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity.
    Kim J; Kim SJ; Chang YS; Park WS
    Retina; 2014 Jan; 34(1):77-82. PubMed ID: 23807184
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bevacizumab for retinopathy of prematurity.
    Lim LS; Mitchell P; Wong TY
    N Engl J Med; 2011 Jun; 364(24):2360; author reply 2361-2. PubMed ID: 21675897
    [No Abstract]   [Full Text] [Related]  

  • 34. Efficacy of intravitreal injection of anti-vascular endothelial growth factor agents for stage 4 retinopathy of prematurity.
    Cheng HC; Lee SM; Hsieh YT; Lin PK
    Retina; 2015 Apr; 35(4):660-6. PubMed ID: 25313709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bevacizumab for retinopathy of prematurity.
    Gilbert CE; Zin A; Darlow B
    N Engl J Med; 2011 Jun; 364(24):2359-60; author reply 2361-2. PubMed ID: 21675898
    [No Abstract]   [Full Text] [Related]  

  • 36. Therapeutic effect of intravitreal anti-VEGF drugs on retinal neovascularization in diabetic retinopathy.
    Jiang G; Han X; Qiao K; Liu S
    Minerva Med; 2024 Apr; 115(2):218-220. PubMed ID: 35838253
    [No Abstract]   [Full Text] [Related]  

  • 37. Retinopathy of Prematurity: Intravitreal injections of bevacizumab: timing, technique, and outcomes.
    Mintz-Hittner HA
    J AAPOS; 2016 Dec; 20(6):478-480. PubMed ID: 27816750
    [No Abstract]   [Full Text] [Related]  

  • 38. Laser-ranibizumab treatment for retinopathy of prematurity in umbral-preumbral disease. Three years of experience.
    Orozco-Gómez LP; Hernández-Salazar L; Moguel-Ancheita S; Ramírez-Moreno MA; Morales-Cruz MV
    Cir Cir; 2011; 79(3):207-214, 225-32. PubMed ID: 22380989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of VEGF Inhibition in the Treatment of Retinopathy of Prematurity.
    Eldweik L; Mantagos IS
    Semin Ophthalmol; 2016; 31(1-2):163-8. PubMed ID: 26959143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Apelin in epiretinal fibrovascular membranes of patients with retinopathy of prematurity and the changes after intravitreal bevacizumab.
    Zhang Y; Jiang YR; Lu Q; Yin H; Tao Y
    Retina; 2013 Mar; 33(3):613-20. PubMed ID: 23296045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.